TY  - GEN
AU  - Fasching,Peter A
AU  - Loibl,Sibylle
AU  - Hu,Chunling
AU  - Hart,Steven N
AU  - Shimelis,Hermela
AU  - Moore,Raymond
AU  - Schem,Christian
AU  - Tesch,Hans
AU  - Untch,Michael
AU  - Hilfrich,Jörn
AU  - Rezai,Mahdi
AU  - Gerber,Bernd
AU  - Costa,Serban Dan
AU  - Blohmer,Jens-Uwe
AU  - Fehm,Tanja
AU  - Huober,Jens
AU  - Liedtke,Cornelia
AU  - Weinshilboum,Richard M
AU  - Wang,Liewei
AU  - Ingle,James N
AU  - Müller,Volkmar
AU  - Nekljudova,Valentina
AU  - Weber,Karsten E
AU  - Rack,Brigitte
AU  - Rübner,Matthias
AU  - von Minckwitz,Gunter
AU  - Couch,Fergus J
TI  - BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study
SN  - 1527-7755
PY  - 2019///1003
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - BRCA1 Protein
KW  - genetics
KW  - BRCA2 Protein
KW  - Bevacizumab
KW  - administration & dosage
KW  - Cyclophosphamide
KW  - Disease-Free Survival
KW  - Docetaxel
KW  - Epirubicin
KW  - Female
KW  - Genotype
KW  - Germ-Line Mutation
KW  - Humans
KW  - Neoadjuvant Therapy
KW  - Receptor, ErbB-2
KW  - metabolism
KW  - Triple Negative Breast Neoplasms
KW  - blood
N1  - Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1200/JCO.2017.77.2285
ER  -